Annexon (ANNX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.28
- Estimate
- -$0.24
- Surprise
- -15.2%
- Score today
- 4.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Annexon (ANNX) reported a wider loss than forecast — adjusted EPS of -$0.28 against the -$0.24 estimate (a 15.2% shortfall).
Coverage in the report window
- Citizens Upgrades Annexon to Market Perform — benzinga, 2026-08-13
- Annexon Q2 EPS $(0.28) Misses $(0.24) Estimate — benzinga, 2026-08-12
- Annexon Adds Month 24 Dual Primary Endpoint To Complement Current Month 15 Primary Endpoint In Phase 3 ARCHER II Trial A — benzinga, 2026-08-12
Where TrendMatrix's rating stands now
TrendMatrix currently rates ANNX Sell at 4.5/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's -15.2% surprise compares with a +7.7% four-quarter average. Next scheduled report: 2027-03-29.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $17.00 vs price $3.57 — ratio 4.8×). Rejected, falling back to technical TP.
- Quality below floor (1.7 < 4.0)
- Momentum score 2.5/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.57
- Price target
- $4.43
- Stop
- $3.44
- Upside to target
- +24.1%
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
ANNX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $747.8M
- P/E (fwd)
- -3.5
- 52-week range
- $2.67–$7.18
- Off 52-week high
- 50.3%
- RSI (14)
- 45
- Volume vs avg
- 0.87×
- Score today
- 4.5/10